Loading…
Cohance Lifesciences Limited, a drug manufacturer in Hyderabad, India, was cited for significant Current Good Manufacturing Practice (CGMP) violations in finished pharmaceutical products, rendering them adulterated. During an FDA inspection in August 2025, the company failed to conduct thorough investigations of batch failures and quality discrepancies, specifically lacking adequate root-cause analysis and corrective/preventive actions (CAPA), as demonstrated by inadequate investigation of customer complaints regarding tablet deterioration across multiple batches. The violations indicate that the company's manufacturing methods, facilities, and controls do not conform to federal regulations under 21 CFR parts 210 and 211.